Cell therapy weekly: adult tendon regeneration achieved following autologous stem cell treatment

This week: results have been published from a first-in-human comprehensive immunohistochemical evaluation of adult tendon repair following injection of autologous stem cells, Chimeric Therapeutics has entered into an exclusive licensing agreement with the University of Pennsylvania for the first CDH17 CAR-T therapy, and a next-generation microbioreactor has been launched by Cytena Bioprocessing Solutions. The news highlights: Adult tendon regeneration achieved following autologous stem cell treatment Chimeric licenses novel solid tumor CAR-T therapy from world-renowned cell therapy center Next-generation microbioreactor launched by Cytena Bioprocess Solutions   Adult tendon regeneration achieved following autologous stem cell treatment InGeneron (TX, USA) has announced the...